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Refractory depression – mechanisms and efficacy
of radically open dialectical behaviour therapy
(RefraMED): findings of a randomised trial on
benefits and harms
Thomas R. Lynch, Roelie J. Hempel, Ben Whalley, Sarah Byford, Rampaul Chamba, Paul Clarke,
Susan Clarke, David G. Kingdon, Heather O’Mahen, Bob Remington, Sophie C. Rushbrook, James Shearer,
Maggie Stanton, Michaela Swales, Alan Watkins and Ian T. Russell
Background
Individuals with depression often do not respond to medication
or psychotherapy. Radically open dialectical behaviour therapy
(RO DBT) is a new treatment targeting overcontrolled personality,
common in refractory depression.
Aims
To compare RO DBT plus treatment as usual (TAU) for refractory
depression with TAU alone (trial registration: ISRCTN 85784627).
Method
RO DBT comprised 29 therapy sessions and 27 skills classes over
6 months. Our completed randomised trial evaluated RO DBT for
refractory depression over 18 months in three British secondary
care centres. Of 250 adult participants, we randomised 162 (65%)
to RO DBT. The primary outcome was the Hamilton Rating Scale
for Depression (HRSD), assessed masked and analysed by
treatment allocated.
Results
After 7 months, immediately following therapy, RO DBT had
significantly reduced depressive symptoms by 5.40 points on the
HRSD relative to TAU (95% CI 0.94–9.85). After 12 months (pri-
mary end-point), the difference of 2.15 points on the HRSD in
favour of RO DBT was not significant (95% CI –2.28 to 6.59); nor
was that of 1.69 points on the HRSD at 18months (95%CI –2.84 to
6.22). Throughout RO DBT participants reported significantly
better psychological flexibility and emotional coping than con-
trols. However, they reported eight possible serious adverse
reactions compared with none in the control group.
Conclusions
The RO DBT group reported significantly lower HRSD scores than
the control group after 7 months, but not thereafter. The imbal-
ance in serious adverse reactions was probably because of the
controls’ limited opportunities to report these.
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Major depressive disorder is a recurrent, disabling condition
causing substantial impairment in psychosocial functioning and
quality of life.1 Only one-third of individuals respond fully to anti-
depressant medication and only half to psychological treatment.2
Recently treatments developed for refractory depression have
achieved small-to-moderate effect sizes.3 Treatments are seldom
effective owing to comorbidity, especially personality disorders.4
About half of patients with unipolar depression meet criteria for
comorbid personality disorders, with higher rates among those
with chronic or treatment-resistant depression.4,5 The commonest
personality disorders among individuals with depression
show excessive inhibitory control or overcontrol, including cluster
A (paranoid personality disorders) and cluster C (obsessive–
compulsive and avoidant personality disorders) – those that
respond poorly to personality disorder treatments.6,7 The core
characteristics of overcontrolled personality disorder are:
cognitive and behavioural rigidity; strong desire to control
one’s environment; restrained emotional expression; limited
social interaction; and problems with close relationships
because of aloofness, distancing, mistrust and fear of rejection or
criticism.8
Radically open dialectical behaviour therapy (RO DBT), a novel
transdiagnostic psychotherapy, aims to address this rigid coping
style.9 Earlier versions of RO DBT showed promise in two pilot ran-
domised trials of patients with refractory depression and comorbid
personality disorders.10,11 This trial aimed to assess the efficacy of
RO DBT for refractory depression,12 and whether RO DBT causes
identifiable harms.13
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Method
Design
Refractory depression: mechanisms and effectiveness of radically
open-dialectical behaviour therapy (RefraMED) was a three-
centre parallel-group randomised trial that compared RO DBT
plus treatment as usual (TAU) with TAU alone (trial registration:
ISRCTN 85784627). After an internal pilot in one centre, shortage
of therapists reduced recruitment below the target rate. So we
extended our recruitment period from 24 months to 32; and
followed the last 27 participants for 12 months (the primary end-
point) rather than 18.
Participants
Patients were eligible for the RefraMED trial if they: were 18 years or
older; had an IQmore than 70; spoke English well enough to partici-
pate; had a current diagnosis of major depressive disorder according
to the Structured Clinical Interview for DSM-IV-TR (SCID)-I;14
had refractory depression, defined as either chronic depression,
that is depression lasting at least 2 years, or treatment-resistant
depression, that is recurrent depression (which we operationalised
as two or more previous episodes) which has not responded to an
adequate dose of anti-depressant medication (ADM) for at least 6
weeks in the current episode; and had a Hamilton Rating Scale
for Depression (HRSD)15 score of at least 15. As we had developed
RODBT specifically for overcontrol, we excluded patients who: met
criteria for bipolar disorder, psychosis or dramatic-erratic personal-
ity disorders in SCID-II;16 had a primary diagnosis of substance
dependence; or were currently receiving or waiting for standard
DBT. We recruited these patients in three National Health
Service (NHS) secondary care centres already delivering standard
DBT for dramatic-erratic personality disorders – Dorset and
Hampshire in England, and North Wales.13
Interventions
TAU
As all three centres seek to deliver best practice, that was the natural
control treatment. All participants received TAU, including pre-
scribed antidepressant medication or psychotherapy.13 Participants
in the control group could also access any treatment from the
NHS or privately, except standard DBT. At each follow-up assessors
asked participants to report their antidepressant medication and
adherence to it, and psychotherapy accessed since their previous
assessment or in the 6 months before their baseline assessment.
RO DBT
RODBT is a transdiagnostic therapy designed to address a spectrum
of disorders that are difficult to treat, notably chronic depression.9 It
differs from other psychotherapies, notably by encouraging social
bonding through emotional expression. At the time of the trial RO
DBT comprised 29 weekly individual therapy sessions each lasting
an hour and 27 skills training classes each lasting 2.5 h.9,12 The RO
DBT lesson plan (supplementary Table 1 available at https://doi.
org/10.1192/bjp.2019.53) included newRODBT lessons9 and stand-
ard DBT lessons.17 RO DBT began soon after participants learned
their treatment allocation. Although they continued to receive anti-
depressant medication as prescribed, we strongly discouraged them
from seeking additional psychotherapy during RO DBT.
The RO DBT developer (T.R.L.) did not contribute to treatment
delivery. He led the 10-day programme to train the 23 recruited
therapists – 8 in Dorset, 10 in Hampshire and 5 in North Wales;
and supervised them thereafter. Two were men, and ages ranged
from 32 to 61 years. All therapists were standard DBT therapists
with a minimum of 3 years clinical experience. To be recruited,
therapists had to submit three treatment tapes rated as adherent
on the standard DBT Adherence Coding Scale – the recognised
measure of adherence in standard DBT,18 relevant also to RO
DBT. All therapists attended weekly team meetings, to enhance
treatment adherence and reduce therapist burnout. We maintained
treatment fidelity across the trial by applying the standard DBT
scale18 to randomly sampled sessions; and feeding scores back to
therapists and their site leaders.
Outcome measures
Primary outcome
The primary outcome was the severity of depressive symptoms 12
months after randomisation, that is 5 months after the end of treat-
ment. Trained assessors measured this by the 17-item HRSD.15
Participants completed the HRSD at four points – baseline, and 7
(immediately after treatment), 12 and 18 months after randomisa-
tion. We chose 7 months rather than 6, when most clients were
still attending treatment sessions, to make RefraMED more com-
parable with other trials that assess response to treatment immedi-
ately after that treatment. We judged it most useful to evaluate RO
DBT after a full year, when remission is most important, even
though psychotherapies are usually evaluated immediately after
the end of therapy.
Secondary outcomes
We assessed remission from HRSD scores and psychosocial func-
tioning measured by the Longitudinal Interval Follow-up
Evaluation – Range of Impaired Functioning Tool (LIFE-RIFT):19
we defined full remission as an HRSD score below 8 and an LIFE-
RIFT score below 13; and partial remission as an HRSD score
below 15 and an LIFE-RIFT score below 13 points.
We measured suicidal ideation using the assessor-rated
Modified Scale for Suicidal Ideation (MSSI);20 total scores less
than nine show low ideation.
After 3 months, and the other four points, we collected data on
the following potential mediating variables.
(a) Acceptance & Action Questionnaire-II (AAQ-II)21 measuring
psychological inflexibility.
(b) Emotional Approach Coping (EAC) scale22 measuring emo-
tional processing and emotional expression.
(c) Patient Health Questionnaire-9 (PHQ-9)23 measuring depres-
sion severity.
(d) The three-item Social Support Questionnaire (SSQ-3)24 meas-
uring responders’ satisfaction with support.
At baseline we also recorded potential moderating variables,
notably age, gender and marital status.
Sample size
Twopilot studies of an earlier but similar version of RODBT for refrac-
tory depression showed effect sizes at end of treatment of 0.8511 and
0.71.10 We aimed to recruit enough participants with analysable data
to yield 80% power to detect as statistically significant at the 5% level
a standardised difference of 0.4 between RO DBT and TAU. We
judged that clinicians and the UK National Institute for Health and
Care Excellence would consider this, equivalent to a mean difference
of two points on the HRSD, to be ‘clinically important’.
If there were no correlation between patients with the same
therapist, a sample of 200 participants with analysable data would
detect such a difference. As we aimed to collect analysable data
from at least 83% of participants, we increased our target to 240.
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To focus on the mechanisms of RO DBT we randomised in the ratio
3 : 2 by allocating 144 ‘unclustered’ patients to RO DBT and 96 to
TAU. However, participants in the RO DBT group cluster by ther-
apist. To allow for an intratherapist correlation coefficient (ICC) of
0.025 between HRSD scores, and an average cluster size of 11
participants for each of the expected 16 therapists, we increased
the RO DBT sample size to 180, yielding the same statistical
power as 144 unclustered participants. Thus, we aimed to random-
ise 276 patients – 180 to RO DBT and 96 to TAU. We planned no
interim analysis or stopping rule apart from that imposed by
funding.
Randomisation and masking
Once we had confirmed eligibility and received informed consent
through the form approved by Hampshire Research Ethics
Committee, we randomised participants between treatments. We
used three stratifying variables to ensure balance between groups –
early or late onset of depression, HRSD score above or below 25,
and presence or absence of personality disorders. Within the RO
DBT group, we randomised participants between available thera-
pists so as to use as many as feasible of the treatment slots at each
centre. To minimise risk of subversion, the Swansea Trials Unit
used dynamic randomisation to make these allocations stochastic-
ally rather than deterministically.25 They emailed the resulting allo-
cations to the trial manager for dissemination to participants and
study therapists, but not assessors.
To keep assessors masked to treatment allocations they: con-
ducted assessments away from treatment centres; asked participants
not to reveal their allocations during assessments; and avoided clin-
ical notes after initial assessment. If an allocation were revealed, we
remasked by using another assessor for later assessments. If the allo-
cation were revealed during assessment, we used the unmasked
ratings; this happened 17 times at month 7, 12 times at month 12
but not at all at month 18.
Assessor reliability
A clinical psychologist experienced in administering SCID and
HSRD in clinical trials (H.O’M.) trained assessors to administer
all these outcome measures. The minimum requirement for
RefraMED assessors was a degree in psychology or closely related
field. In reality all assessors had postgraduate qualifications,
mainly MSc, DClinPsy or PhD.We discussed queries at weekly con-
sensus meetings. We assessed interrater reliability for the HRSD at
9-month intervals across nine assessors. We analysed the reliability
of individual items, more rigorous than analysing total scores.
Across all measurements Krippendorff’s alpha was 0.89 (95% CI
from 0.86 to 0.92), implying ‘very good’ to ‘near perfect’ interrater
reliability.26
Statistical methods
To create a data-set for analysis, we linked study data-sets by ran-
domisation codes. We validated this database by comparing infor-
mation across sources, and by entering data twice. We scored all
measures according to their published rules for imputing missing
data.
We used the lmerTest package for the statistical language R to fit
linear mixed-effects models to primary and secondary outcomes
over the 18 months from baseline.27 Covariates included treatment
allocated, treatment centre, baseline HRSD score, early or late onset
of depression, and presence or absence of personality disorders at
baseline. We used a three-level mixed-effects model to account for
clustering of data by patient and therapist, avoiding the assumption
that all therapists are equally effective. These mixed models are
efficient and unbiased when data are missing at random. Without
suitable auxiliary data we did not impute missing responses, for
example by multiple imputation. However, when fewer than 10%
of items were missing in a given scale, we imputed them by linear
regression using the other scale items as covariates. For each
outcome we estimated the main effects of treatment allocation
and time, and the interaction between them; and compared
groups at months 7, 12 and 18 by treatment allocated.
In assessing remission from depression, we used Button’s criter-
ion of 17.5% change in HRSD scores from baseline.28 We refitted
our mixed models using the Bayesian software Stan, and the asso-
ciated R package ‘brms’.29 We assessed heterogeneity in therapist
performance by ICCs, and simulated prognoses for future patients
on RO DBT. Analyses post hoc estimated posterior odds ratios30
for hypotheses of interest. We derived remission rates from predic-
tions based on continuous outcomes, so did not need to test for
differences in these rates directly.
Serious adverse events
Our report to the National Institute for Health Research (NIHR)
describes how we monitored serious adverse events (SAEs).13 The
chief investigator reviewed these immediately, and reported them
to the Data Monitoring & Ethics Committee (DMEC) every year,
or immediately if there was suspicion of an unexpected serious
adverse reaction.
Ethical approval and conduct
Before recruiting patients, we gained approval from the Hampshire
Research Ethics Committee (National Research Ethics Service refer-
ence 11/SC/0146) and the Research Governance Department of the
University of Southampton, the sponsor of this trial. We asked trial
participants for consent on three occasions: before telephone
screening; before baseline assessment; and before randomisation.
Patient and public inclusion
The NIHR Mental Health Research Network and ‘Involve’, the
national advisory group on public engagement, helped us recruit
service users – two to the Trial Steering Committee and two to
the Trial Management Group. These users contributed to patient
information leaflets, managing the trial and disseminating findings.
Data availability and role of the funding source
All non-confidential data and syntax for analyses reported
here are available online (https://zenodo.org/record/1442883).
The Efficacy & Mechanism Evaluation Programme, funded by
the Medical Research Council and administered by the NIHR,
funded this trial by grant 09/150/12. NIHR monitored the trial
and appointed the independent members of the Trial Steering
Committee and Data Monitoring & Ethics Committee. The
grant holders were responsible for: study design; collecting, ana-
lysing, and interpreting data; writing this paper; and submitting
it for publication.
Results
Recruitment
Figure 1 shows the flow of participants through the RefraMED trial:
we randomised 250 eligible patients, 162 (65%) to RO DBT and 88
to TAU (the control group). Recruitment started in Dorset inMarch
2012 with an internal pilot; started in Hampshire and North Wales
in September 2012; and continued until April 2015. Of the 250 ran-
domised participants, 170 (68%) came from secondary care,
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Primary care – 1703
Secondary care – 849
Self referred – 101
Other – 25
Primary care – 55
Secondary care – 170
Self-referred – 19
Other – 6
Referred
2678
Screened by phone
for eligibility – 913
Interviewed for
eligibility – 444
Randomised
250
Not assessed – 1765
• Did not respond to contact – 1194
• Declined in responce to contact – 437
• Not contacted – 134
Excluded after phone screen – 340
• Ineligible – 211
• Unable to commit to study – 129
 • Booked interview but did not attend – 100
 • Eligible but declined interview – 29
Passed phone screen but did not attend interview – 129
Excluded after assessment interview – 160
• Failed exclusion criterion e.g. psychosis or borderline 
      personality disorder – 78
• HRSD score < 15 – 49
• Declined to commit to study – 15
• Neither chronic nor recurrent – 5
• Other – 13
Eligible but declined participation – 34
Allocated to RO-DBT – 162
• Received ≥ 4 RO-DBT sessions – 147
• Received ≤ 3 RO-DBT sessions – 15
Allocated to treatment as usual
(TAU) 88
Withdrew from study – 12
Lost to follow-up – 12
Withdrew from study – 3
Lost to follow-up – 0
Not followed-up at 18 months – 16
Withdrew from study – 3
Lost to follow-up – 3
Followed-up at 12 months – 130
Did not attend – 5
Analysed – 130
Followed-up at 18 months – 113
Analysed – 112
Followed-up at 18 months – 55
Analysed – 55
Followed-up at 7 months – 124
Did not attend – 14
Analysed – 121
Followed-up at 7 months – 62
Did not attend – 5
Analysed – 60
Followed-up at 7 months – 62
Did not attend – 8
Analysed – 62
Withdrew from study – 12
Lost to follow-up – 6
Withdrew from study – 2
Lost to follow-up – 1
Not followed-up at 18 months – 11
Withdrew from study – 1
Lost to follow-up – 0
Allocation
Follow-up at 7 months
Follow-up at 12 months
Follow-up at 18 months
Fig. 1 CONSORT diagram showing flow of participants through the Refractory depression: mechanisms and effectiveness of radically open-dialectical behaviour therapy (RefraMED) trial, including numbers
analysed at each assessment.
HRSD, Hamilton Rating Scale for Depression; RO DBT, radically open dialectical behaviour therapy.
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55 (22%) from primary-care database searches, 19 (8%) from self-
referral and 6 (2%) from other sources, notably private practitioners.13
Of 162 participants allocated to the RO DBT group, 34 (21%)
withdrew, including 10 who attended no sessions, 4 who attended
only one or two sessions; and 10 prevented from continuing
because of work or family commitments. If participants did not
attend a follow-up appointment after 7 or 12 months, we asked
them to attend the next scheduled follow-up. For example, 6 of
the 14 RO DBT participants who did not attend their appointment
after 7 months did attend their appointment after 12 months. This
explains why we analysed more participants after 12 months (130)
than after 7 (124).
Of the 88 participants in the control group, 22 (25%) withdrew,
including 9 because they were not happy with being allocated to
TAU. Only one of those withdrawing from treatment agreed to
stay in the study for follow-up interviews. So the proportion of par-
ticipants analysed at month 12 did not differ significantly between
groups (χ2 = 0.71; d.f. = 1; P = 0.40).
Baseline data – demographic and clinical
Of the 250 participants, 164 (66%) were women; 138 (55%) were aged
between 35 and 55; 232 (97% of 238 responders) described their eth-
nicity as White; 106 (42%) reported being in a stable relationship; and
82 (34% of 241 responders) had a university qualification. A total of
92 participants (37%) reported a first depressive episode before
the age of 16; 179 (84% of 213 responders) were chronically
rather than recurrently depressed; and 191 (82% of 234 responders)
had previously received psychotherapy. Our sample also showed
high comorbidity: 217 (87%) with at least one Axis I disorder and
197 (79%) with at least one Axis II disorder; only 9 (4%) had no
psychiatric comorbidity.13 Our report also confirms that our
adaptive randomisation procedure was effective in balancing the
characteristics of participants across groups; treatment centres were
also generally comparable in terms of participants’ characteristics.13
Delivery of therapy
Of 23 therapists we trained, 1 did not provide therapy within
RefraMED. The number of participants seen by the other therapists
ranged from 1 to 17, with amean of 6.9 and amedian of 7. Themean
number of individual sessions attended by participants was 22.9
(s.d. = 6.9; 79% of the 29 planned); and the mean number of
group sessions attended was 19.9 (s.d. = 7.6; 74% of the 27 planned).
Treatment fidelity
We rated 273 (9%) tapes; and adjudged 221 (81%) of these adherent
with a score of 4.0 or more.
Primary outcome: depressive symptoms measured
by HRSD
Table 1 and Fig. 2 compare HRSD and the five secondary continu-
ous outcome variables between groups across all follow-ups (a more
detailed version of Table 1 is available in supplementary Table 2).
Depressive symptoms in both groups improved continuously
from baseline to 18 months. By the end of therapy at seven
months, RO DBT had substantially reduced depressive symptoms
relative to TAU by 5.40 HRSD points (95% CI 0.94–9.85; effect
size 1.03; P = 0.02). The RO DBT group maintained their
Table 1 Hamilton Rating Scale for Depression and secondary outcomes by group at 0, 7, 12 and 18 months (see supplementary Table 2 for a more
detailed version of this table)
Dependent variable
RO DBT group, adjusted
mean
TAU, adjusted
mean Difference 95% CI P Evidence ratio (d > 0)a
Hamilton Rating Scale for Depression
Baseline 23.14 23.14 −0.05 −4.44 to 4.34 0.979 1.10
7 months 15.34 20.73 −5.40 −9.84 to −0.94 0.023 46.30
12 months 14.19 16.34 −2.15 −6.69 to 2.28 0.290 5.53
18 months 13.79 15.48 −1.69 −6.22 to 2.84 0.424 4.67
Action and Acceptance
Questionnaire
Baseline 38.53 38.53 0.00 −7.87 to 7.87 1.000 0.77
7 months 33.12 36.48 −3.37 −7.95 to 1.21 0.096 30.47
12 months 32.56 37.50 −4.94 −9.44 to −0.45 0.040 121.82
18 months 30.69 36.17 −5.48 −9.44 to −1.52 0.014 55.98
Emotional Approach Coping
Baseline 16.10 16.10 0.00 −3.83 to 3.83 1.000 1.00
7 months 18.38 16.89 1.50 −0.84 to 3.83 0.132 36.36
12 months 18.64 15.10 3.55 1.22 to 5.87 0.017 3242.24
18 months 19.31 16.33 2.98 0.84 to 5.12 0.012 278.72
Modified Scale for Suicide Ideation
Baseline 7.72 7.72 −0.00 −2.92 to 2.92 1.000 0.95
7 months 4.66 6.50 −1.84 −4.49 to 0.80 0.150 17.58
12 months 2.46 3.90 −1.44 −4.03 to 1.15 0.229 5.14
18 months 2.04 1.60 0.45 −2.48 to 3.37 0.753 1.52
Patient Health Questionnaire-9
Baseline 19.24 19.24 −0.00 −5.02 to 5.02 1.000 0.86
7 months 13.24 16.69 −3.45 −6.61 to −0.29 0.041 30.82
12 months 13.04 15.96 −2.92 −6.04 to 0.20 0.058 33.64
18 months 12.87 16.10 −3.23 −6.05 to −0.40 0.030 12.39
Social Support Questionnaire
Baseline 0.15 0.15 0.01 −0.44 to 0.46 0.952 0.92
7 months 0.15 −0.07 0.22 −0.23 to 0.67 0.279 0.15
12 months 0.25 −0.05 0.30 −0.15 to 0.75 0.157 0.10
18 months 0.27 −0.13 0.40 −0.08 to 0.87 0.093 0.20
RO DBT, radically open dialectical behaviour therapy; TAU, treatment as usual; OR, odds ratio.
a. Evidence ratio (d > 0) for hypothesis that RO DBT is better than TAU.
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improvement in depressive symptoms at 12 and 18 months, but the
control group improved more after 7 months, reducing the differ-
ence between groups. The difference of 2.15 HRSD points at 12
months exceeded our prior target of 2 points but was not statistically
significant (95% CI −2.28 to 6.59; effect size 0.41; P = 0.29). At 18
months the difference fell to 1.69 HRSD points (95% CI −2.84 to
6.22; effect size 0.32; P = 0.42). Thus, our planned contrasts revealed
a statistically significant difference between RO DBT and TAU after
7 months, but not after 12 or 18 months.
In contrast Bayesian analysis post hoc provided evidence that
RO DBT was superior to TAU across all follow-ups: the posterior
odds ratio was: 46 at 7 months – suggesting ‘strong’ evidence;30
and 5.5 and 4.7 at 12 and 18 months, respectively – suggesting ‘posi-
tive’ evidence.30 Figure 3 displays the posterior probability that RO
DBT achieved the range of effects on the x-axis. The likely causes of
the trial’s reduced power was the combination of under recruitment
and unexpectedly large therapist heterogeneity, yielding an ICC of
0.14, much larger than the ICC of 0.025 postulated in our power
analysis. The most and least effective therapists, judged by clinical
outcomes of their participants, differed by 2.6 HRSD points, equiva-
lent to a standardised effect size of 0.43.
Remission rates
Using primary criteria, full remission rates were low in both groups:
1%, 8% and 7% for RODBT and 0%, 0% and 1% in controls, at 7, 12
and 18 months, respectively; and partial remission rates were higher
for the RO DBT group – 23%, 26% and 33% at successive assess-
ments – than in control group – 6%, 22% and 24%. Using the criter-
ion of ‘worthwhile’ change, namely 17.5% reduction in symptoms
from baseline,28 remission rates were: 59%, 69% and 59% in the
RO DBT group at 7, 12 and 18 months, respectively; and 27%,
48% and 41%, in the control group.
To help patients and clinicians interpret our findings, we simu-
lated likely outcomes for new patients, estimating that, for every 100
new patients, 32 would achieve 17.5% improvement in symptom
scores after 12 months by choosing RO DBT rather than TAU,
whereas 10 would deteriorate by the same criterion, and 58 would
remain essentially unchanged.
Secondary continuous outcomes
The RO DBT group achieved significant gains in psychological
flexibility and emotional coping relative to controls throughout
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and 18.
RO DBT, radically open dialectical behaviour therapy; TAU, treatment as usual.
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the trial (Fig. 2, Table 1 and supplementary Table 2). Mean AAQ
scores, measuring psychological inflexibility decreased over time,
especially after RO DBT; the effect size increased from 0.49
(medium) after 7 months to 0.72 (large) after 12, and 0.79 after
18. EAC scores, measuring emotional coping, increased after RO
DBT, but not after TAU; the effect size increased from 0.32
(small) after 7 months to 0.76 (large) after 12 months and 0.64
(also large) after 18.
However, Table 1 (and supplementary Table 2) shows no sig-
nificant advantage for RO DBT in suicidal ideation or perceived
social support. Mean MSSI suicidal ideation scores remained low
throughout the trial for both groups; and although mean SSQ (per-
ceived social support) scores increased after RO DBT, the difference
between groups was never significant.
SAEs
We received reports of 32 SAEs – 4 from the 88 participants
allocated to TAU and 28 from the 162 participants allocated to
RO DBT;13 none of these led to withdrawal from the trial. In the
RODBT group, 21 participants experienced a single event; 2 experi-
enced two events each; and 1 participant experienced three events.
Thus, 24 people in the RO DBT group experienced SAEs. We
judged that all 4 events in the control group and 13 in the RO
DBT group were ‘definitely not related’ to the study intervention,
for example a leg fracture and one death from natural causes.
We judged that another eight were ‘unlikely to be related’, for
example recurrent non-suicidal self-injury starting before the trial.
Of the remaining eight SAEs, all from the intervention group, we
judged that five were ‘possibly related’ to RO DBT, including two
overdoses, and three were ‘probably related’, including a prevented
suicide attempt. Nevertheless, we classed none of those eight serious
adverse reactions as ‘suspected unexpected’ requiring immediate
reporting to the Research Ethics Committee.
Thus, all eight serious adverse reactions judged as potentially
related to RO DBT occurred in the intervention group (Fisher’s
exact test; one-tailed P = 0.004). However, trial assessors saw par-
ticipants in the control group only at the three follow-up inter-
views, so that SAE reporting relied on their volunteering
relevant information. In contrast trial therapists saw the partici-
pants in the RO DBT group twice a week, and they completed
diary cards reporting on suicidal ideation and self-harm. We
tried to ameliorate reporting bias by asking participants’ general
practitioners to report any SAEs they encountered. However, no
one outside the RefraMED team reported an SAE: participants
in the control group reported all four SAEs either during assess-
ment or to the trial office. In the RO DBT group therapists
reported 23 (82%) SAEs, and participants reported only 5. We
believe the imbalance was because of these gross differences in
reporting opportunities and encouragement from therapists to
use those opportunities. As in both previous trials of RO
DBT,10,11 there were no suicides in this trial. For all these
reasons the Data Monitoring Committee saw ‘no reason to
suspect RO DBT had adverse effects on patients’.
Discussion
Principal findings
In participants with refractory depression, RO DBT was not statis-
tically superior to TAU on the HRSD at our primary end-point of 12
months after randomisation, despite achieving the target moderate
effect size of 0.40. However, it was substantially better than TAU
immediately after treatment, with an effect size of 1.03, much
larger than reported by previous trials of psychotherapy for
refractory depression.4 The later fall in effect size stems from
rapid improvement during RO DBT, and initially slow but acceler-
ating improvement during TAU. Bayesian analysis post hoc gener-
ated ‘positive’ evidence of the superiority of RO DBT over 18
months; and suggests that 22% (i.e. 32% less 10%) more patients
would experience ‘worthwhile change’ at 12 months by choosing
RO DBT over TAU.
Psychological outcomes
RODBT aims to help individuals with rigid psychological and inter-
personal styles learn flexibility. Reassuringly participants in the RO
DBT group reported significantly better psychological flexibility
than the controls throughout the 18 months of follow-up. RO
DBT also aims to encourage appropriate expression of emotion to
avoid isolation. Again, the RO DBT group reported significantly
better emotional processing throughout these 18months. Both find-
ings suggest that participants continue to use and improve their RO
DBT skills. However, there was no significant advantage for RO
DBT in suicidal ideation or perceived social support. Throughout
the trial suicidal ideation was low in both groups; although this
decreased further over time in both groups, the difference was
never significant. This finding was probably because of both
groups continuing to receive treatment and support either from
the trial or from the NHS. Although social support scores increased
after RO DBT and decreased after TAU, the difference between
groups was never significant.
Strengths
RODBT is the first treatment known to us to target deficits in social
signalling as the main problem underlying overcontrolled emotional
loneliness. We designed RefraMED as a hybrid between a phase II
efficacy trial and a phase III effectiveness trial. The former yielded
strengths in: the consistency of both intervention and assessment;
allocating therapists to patients at random rather than allocating
difficult patients to the most skilled therapists.13 The latter yielded
strengths in: minimising exclusion criteria thus including a wide
range of patients with depression and maximising generalisability;
enabling the treatment developer to train therapists rather than
provide therapy; and facilitating cost-effectiveness analysis.13 See
supplementary Table 3 for the CONSORT checklist.
Limitations
There are a range of definitions of refractory depression and
treatment-resistant depression which should be taken into
account when considering the generalisability of our findings.
Despite our best efforts to recruit 276 participants, and analyse
229 (83%) of them, we recruited only 250 (91% of target) and
analysed only 190 (76%); we also encountered unexpectedly large
therapist heterogeneity. Despite achieving our target effect size at
12 months, the resulting loss of power meant our pre-planned
analyses did not achieve statistical significance beyond month 7.
Interpretation
RefraMED was the first multicentre trial of RO DBT. Although RO
DBT greatly improved depressive symptoms by the end of
treatment, our planned analyses were not statistically significant
thereafter. Bayesian analysis post hoc suggests that RO DBT was
superior to TAU throughout, but this effect was not clinically
significant after month 7.
RO DBT does not label depression as the primary problem.
Instead it targets emotional overcontrol – a maladaptive personality
style known to predict the development of chronic internalising dis-
orders such as refractory depression. Overcontrolled personality
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disorders, including obsessive–compulsive personality disorders,
are more common than undercontrolled personality disorders;
and patients’ innate capacity to tolerate distress, delay gratification
and avoid public displays of emotion make their problems less
noticeable, and they are less likely to seek mental health treatment.
Hence, it is reassuring that RO DBT improved psychological
flexibility and emotional processing over 18 months in a highly
symptomatic population, most of whom experience several
mental health problems.
Implications for future research
Given the recurring nature of depression, and RO DBT’s aim of
changing maladaptive personality, future studies should investigate
long-term differences between RO DBT and other treatments.
The high proportion of comorbid disorders in RefraMED (96%),
and the evidence that patients with complex mental disorders do
not benefit much from short-term psychotherapy,31 support this
proposal. RO DBT’s transdiagnostic approach justifies testing
RO DBT across a range of conditions, including overcontrolled
personality disorders (clusters A and C), anxiety disorders and
eating disorders.32
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